InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.38
(
0.13%
)
US TECH 100
17,632.00
(
0.12%
)
Dow Jones
38,960.30
(
0.28%
)
Brent Oil
82.65
(
-0.99%
)
Bitcoin
63,281.46
(
0.18%
)
Post# of 251733
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119580
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 208514

Thursday, 07/19/2018 11:15:42 AM

Thursday, July 19, 2018 11:15:42 AM

Post# of 251733
AGN/MOLN.SW report phase-3 AMD data for Abicipar (a/k/a DARPin):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-two-120000138.html

Dosed either bimonthly or quarterly, Abicipar’s efficacy was non-inferior to Lucentis (dosed monthly); however, Abicipar had a numerically higher rate of inflammation, which has long been considered the Achilles heel of this drug.

AGN plans to submit a BLA in 1H19, if all goes well in a pre-BLA meeting with the FDA.

As I’m typing, AGN is -2% and MOLN.SW (the creator of Abicipar) is -13%.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up